Kabiven Peripheral Inj.

Adult administration

For adults, the dosage and infusion rate are determined based on fat removal and glucose metabolism capacity, and the patient's condition, weight, and nutritional requirements decide the dosage and pouch size. For patients in normal nutritional status or mild metabolic stress: Amino acids of 0.7-1.0 g/kg/day (0.10-0.15 g nitrogen/kg). For patients undergoing moderate to severe metabolic stress: Amino acids of 1.0-2.0 g/kg/day.

This medication must be used strictly according to a physician's instructions, and if symptoms of anaphylactic reactions such as fever, chills, rash, or dyspnea occur during use, administration must be discontinued immediately. When used with intravenous calcium-containing preparations, do not mix with ceftriaxone as precipitation may occur; do not use the same infusion device, and ensure infusion lines are thoroughly cleaned during continuous infusion. Use with caution in premature infants or underweight infants due to their lower fat removal ability. Should not be administered to patients with a history of allergic reactions, severe hyperlipidemia, liver dysfunction, blood coagulation disorders, amino acid metabolism disorders, renal failure, acute shock, hyperglycemia, neonates, and infants under the age of two. Administer carefully to patients with renal failure, pancreatitis, liver dysfunction, hypothyroidism, septic conditions, or any disorders of lipid metabolism or electrolyte imbalances. During administration, monitor closely for possible symptoms such as elevated body temperature, chills, nausea, vomiting, increased liver enzymes, thrombotic phlebitis, and, rarely, anaphylactic reactions or blood pressure abnormalities. Serious side effects such as lipid excess syndrome may arise, so regular checks of serum triglyceride levels post-administration are necessary, and blood sugar, electrolytes, liver, and kidney functions should also be monitored closely. This product contains soybean oil and egg phospholipids, hence patients with soybean or nut allergies should take caution. During administration, ensure aseptic procedures are strictly followed to reduce the risk of infection, and do not infuse simultaneously with other substances, such as blood, using the same syringe. There is insufficient evidence for safe use in pregnant or breastfeeding women, therefore should only be administered when the benefits justify the risks. Elderly patients may have reduced physiological functions; thus, the infusion rate should be slow, and dosages adjusted accordingly. Perform blood tests 5–6 hours after administration to avoid interference from lipids in test outcomes. In case of overdose, symptoms such as nausea, vomiting, fluid overload, electrolyte imbalances, and hyperglycemia can occur; if symptoms arise, reduce or cease the infusion rate, and in severe cases, treatments such as dialysis may be necessary. Do not use if the packaging is damaged or the solution is cloudy or separated; mix the solution immediately before use and discard any remaining solution. Store this medication at temperatures between 0 and 25 degrees Celsius, do not freeze, and keep it in unopened packaging.

Serious side effects

• Anaphylactic reactions (hives, skin rashes, severe swelling), dyspnea, rash, fever, chills → severe allergic reactions.
• Problems with breathing, including hyperventilation.
• Increased blood pressure, severe systemic edema.
• Coma → severe edema or urination abnormalities.
• Coma → severe neurological symptoms.

Mild side effects

Occasionally, symptoms such as increased body temperature, chills, nausea/vomiting, transient increase in liver enzymes, thrombotic phlebitis upon peripheral vein administration, hypertension/hypotension, hemolysis, reticulocyte increase, abdominal pain, headache, fatigue, penile rigidity, hyperlipidemia, fat deposition, liver enlargement, spleen enlargement, anemia, leukopenia, thrombocytopenia, blood coagulation abnormalities, coma may occur.

This medication should be stored in a sealed container to prevent exposure to air, and the storage temperature should be maintained between 0 and 25 degrees Celsius. This helps ensure the medication's efficacy is well-maintained and prevents degradation.

Appearance

Consists of three chambers divided internally and external packaging. There is an oxygen absorber pouch between the internal and external packaging. The chambers of the internal pouch are

Package unit

1440ml / bag x 4, 1920ml / bag x 4